ArticleBlood cancer journal2025

CD56 expression modulates NAD+ metabolic landscape and predicts sensitivity to anti-CD38 therapies in multiple myeloma.

Giulia Giorgetti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.